J&J Announces Proposed $5.5 Billion Settlement of 76,000 Ovarian Talc Claims

What J&J agreed to

Johnson & Johnson's July 27 announcement describes a "comprehensive resolution of the remaining talc litigation" negotiated with the plaintiff firms leading the federal MDL and the related state court proceedings. The financial structure has three features worth separating out, because they are easy to blur together.

The commitment is $5.5 billion. That is the figure in J&J's own press release and the number driving the headlines.

The payments are per claim, not a pooled fund. The agreement assigns values to qualifying ovarian cancer claims. Claimants are not dividing a fixed pot.

The total is not capped. This follows from the second point. Because payment is per claim, the aggregate depends on how many claims qualify and participate. Christopher Seeger of Seeger Weiss, who helped negotiate the deal and represents roughly 2,500 talc clients, told Reuters that J&J could ultimately pay $7 billion or more, and that the settlement "assigns specific values to qualifying ovarian cancer claims but does not cap J&J's total payout."

On timing, J&J said the first payment will be no more than $3 billion in 2027, with no additional payments due before 2028. Seeger characterized the pace as paying all claims within roughly 18 months, compared with more than a decade under the bankruptcy plan rejected in 2025.

The company admitted nothing. Erik Haas, J&J's Worldwide Vice President of Litigation, said the company remains "confident the Company would have ultimately prevailed with further litigation" and framed the deal as a way to "put this matter behind it."

The ruling that produced the deal

The timing here is the story. This settlement did not follow a plaintiff verdict or an adverse ruling against J&J. It followed the company's most significant procedural win in the entire litigation, by five days.

On July 22, 2026, U.S. Magistrate Judge Rukhsanah L. Singh, in the District of New Jersey, granted J&J's motion for an order to show cause. She directed plaintiffs' leadership to explain why the remaining pending talc claims should not be dismissed for inability to prove specific causation, the requirement that a plaintiff show the product caused her cancer rather than one of the many other recognized ovarian cancer risk factors.

The order followed a sequence that unfolded over the spring. Six plaintiffs had been selected for the first federal bellwether trials. Plaintiffs designated Dr. Judith Wolf and Dr. Daniel L. Clarke-Pearson as their specific causation experts for those bellwether plaintiffs, according to court reporting. After a May 2026 evidentiary hearing testing those opinions, plaintiffs' counsel withdrew both experts from their bellwether roles, without prejudice, meaning they could in principle be reinstated. J&J then argued that if the plaintiffs' own marquee experts could not distinguish talc from other ovarian cancer risk factors, no plaintiff in the MDL could carry the burden. In its settlement announcement, J&J described plaintiffs as having "effectively conceded their inability to prove specific causation by withdrawing their experts on the topic in two bellwether cases."

Judge Singh declined to characterize her order as a dismissal, writing that "the visceral reaction to J&J's Motion may be that it seeks instant dismissal of all cases in this MDL. The undersigned views it differently," and describing the motion instead as "an opportunity for the parties and the Court to review the status of the record to, perhaps, re-evaluate a better way to manage an aged and complex mass tort MDL, such as this one."

Her analysis of the expert testimony was pointed. Under New Jersey's two-step standard for differential diagnosis, an expert must rule in plausible causes and then rule them out. Singh found that Dr. Wolf did not perform the second step, and that Dr. Clarke-Pearson "could not justify his determinations as to whether to rule out a particular risk factor." She then asked the question that shapes everything that followed: whether "any expert would be capable of reliably evaluating the risk factors for a woman's specific ovarian cancer to determine which risk factor(s) 'substantially contributed' to the disease and which risk factor(s) did not." A special master had separately recommended rejecting a key plaintiff expert's testing methodology, finding it "lacks nearly all of the traditional indicia of reliability."

J&J's public position after the order, attributed to Haas on July 23, was that the ruling brought the cases "one step closer to the inevitable, equitable and appropriate outcome, the complete dismissal of the talc litigation." Five days later the company agreed to pay billions to resolve them. Both sides had reason to deal: J&J bought certainty and eliminated the cost of litigating 76,000 claims, and plaintiffs converted a case in serious jeopardy into fixed per-claim value.

Judge Michael A. Shipp remains the presiding district judge in MDL-2738. Judge Singh is the magistrate judge managing pretrial proceedings.

What the settlement does not cover

Mesothelioma claims are not in this deal. The proposed resolution is specific to ovarian cancer claims. J&J's announcement is titled a resolution of the ovarian talc litigation and lists its mesothelioma settlements separately, saying it had previously settled about 95% of filed mesothelioma lawsuits on a separate track. The unsettled remainder, including cases behind some of the largest talc verdicts on record, is not addressed here. One firm on the plaintiffs' executive committee has described the agreement in broader terms, so anyone with a mesothelioma claim should confirm scope with their own counsel rather than relying on press summaries.

Future claims are excluded. This is the sharpest break from J&J's three failed bankruptcy attempts, each of which sought to resolve future claims through a trust. This agreement covers claims that already exist. Seeger told Reuters that leaving future claims out is precisely what made more money available to current claimants.

Consumer protection and supplier claims were already resolved. J&J settled state consumer protection claims for $700 million with 42 states and the District of Columbia, announced as an agreement in January 2024 and finalized on June 11, 2024. Its talc supplier disputes were resolved separately.

Litigation outside the United States continues. J&J retained talc liabilities and indemnified Kenvue for costs arising from litigation in the United States and Canada. Kenvue UK Limited is separately defending talc claims in England, which this settlement does not touch.

Reading the two different case counts

You will see both 76,000 and roughly 68,000 in coverage this week. Both are accurate, and they count different things. The ~76,000 figure is J&J's count of remaining ovarian talc claims across the federal MDL and related state court dockets combined. Law.com reported that the deal resolves 99.75% of the talc litigation in federal and state courts. The 68,435 pending figure (71,121 total filed) is from the Judicial Panel on Multidistrict Litigation's July 2026 statistics report and counts the federal MDL-2738 docket only. That is the number we track month to month, and it does not include state court filings.